Rockwell Medical Inc  

(Public, NASDAQ:RMTI)   Watch this stock  
Find more results for RMTI
-0.23 (-2.17%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.35 - 10.77
52 week 8.10 - 12.47
Open 10.60
Vol / Avg. 273,541.00/442,398.00
Mkt cap 521.29M
P/E     -
Div/yield     -
EPS -0.51
Shares 50.34M
Beta 1.17
Inst. own 25%
May 21, 2015
Rockwell Medical Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
May 11, 2015
Q1 2015 Rockwell Medical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 26, 2015
Q4 2014 Rockwell Medical Inc Earnings Call - Webcast
Feb 26, 2015
Q4 2014 Rockwell Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -44.18% -39.36%
Operating margin -34.75% -32.40%
EBITD margin - -30.57%
Return on average assets -42.02% -31.75%
Return on average equity -80.97% -61.55%
Employees 283 -
CDP Score - -


30142 S Wixom Rd
WIXOM, MI 48393-3440
United States - Map
+1-248-9609009 (Phone)
+1-248-9609119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rockwell Medical, Inc. is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis (also referred to as dialysis). The Company�s investigational drug, Triferic, also known as Soluble Ferric Pyrophosphate or SFP, delivers iron to the bone marrow in a non-invasive, physiologic manner to hemodialysis patients via dialysate during the regular dialysis treatment. Triferic will substantially improve iron therapy for these patients. The Company successfully completed the two pivotal studies, CRUISE-1 and CRUISE-2, in Triferic's Phase 3 clinical program during fiscal 2013. The Company prepares to launch a generic drug called Calcitriol. Calcitriol is active vitamin D injection and indicated for the treatment of secondary hyperparathyroidism in dialysis patients.

Officers and directors

Robert L. Chioini Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Thomas E. Klema CPA, MBA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 61
Bio & Compensation  - Reuters
Ajay Gupta M.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Raymond D. Pratt M.D. Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Patrick J. Bagley Independent Director
Age: 50
Bio & Compensation  - Reuters
Ronald D. Boyd Independent Director
Age: 52
Bio & Compensation  - Reuters
Kenneth L. Holt Independent Director
Age: 62
Bio & Compensation  - Reuters